Johnson & Johnson says pausing its coronavirus vaccine trials is 'not at all unusual,' as researchers investigate an unexplained illness
- A top Johnson & Johnson executive said Tuesday pausing its coronavirus
vaccinetrials was "not at all unusual" for these massive studies.
- On Monday, J&J confirmed it had paused its ongoing trials after a participant developed an unexplained illness.
- It's the second major vaccine program to halt its trial due to potential safety concerns.
- J&J provided few details around this case. Mathai Mammen, the global head of Janssen research and development at J&J, said it will require "a few days at a minimum" to gather and assess the information.
- The pause, first reported by Stat News, came just weeks after the pharma giant launched the massive study to evaluate whether the vaccine could prevent
A top Johnson & Johnson executive provided few new details on Tuesday about the decision to pause its
On Monday, J&J confirmed it had temporarily halted its vaccine studies after a participant experienced an unexplained illness, the second major setback to hit a late-stage test of an immunization for the novel coronavirus. J&J's stock dropped about 2% on Tuesday.
The pharma giant said it paused all further dosing in the trials after a participant fell ill. The pause in the trial, which is aiming to enroll 60,000 people to determine whether the vaccine is safe and effective, was first reported by Stat News' Matthew Herper.
J&J said the participant's illness was being reviewed by an independent board as well as by company doctors.
"It's not at all unusual for unexpected illnesses that occur in large studies over their duration," Mathai Mammen, the global head of Janssen research and development at J&J, said on a Tuesday earnings call.
Mammen said J&J is committed to being transparent through the process but also needs to learn more about this incident. He estimated it will be "a few days at a minimum" to gather and evaluate the information. The company does not yet know if the person who fell ill received the experimental vaccine or a placebo, Mammen added.
The company didn't share more information about the nature of the illness, citing patient privacy.
"We must respect this participant's privacy," J&J said in a Monday statement. "We're also learning more about this participant's illness, and it's important to have all the facts before we share additional information."
A coronavirus vaccine trial from the British drugmaker AstraZeneca is facing a similar setback. In September, AstraZeneca paused its trial over concerns that a participant might've had an adverse reaction. The UK arm of the trial has resumed, though the US portion of the trial is still paused while being investigated further by the US Food and Drug Administration.
Other late-stage vaccine trials from Pfizer and Moderna are underway, and they could yield results this year.
J&J, the world's largest
The trial had initially expected to yield early results in late-2020 or early 2021. Depending on how long the trial is paused, the findings could be delayed. J&J didn't provide any information about the length of the pause.
This story was originally published on October 12 and was updated on October 13 to include comments from Johnson & Johnson's third-quarter earnings call.
- Kellyanne Conway says her husband was 'cheating by tweeting' his disdain for former President Trump in her new memoir
- The worst for Indian startups is yet to come — be prepared for layoffs, unicorn slowdown and startup shutdowns in 2022
- Not just India, many countries are protecting their wheat to keep daily bread, affordable
- Billionaire wealth rose more in 2 years than in the last 23 years combined
- IT giant Infosys reappoints Salil Parekh as CEO and MD for next five years
- WhatsApp will end support for iOS 10 and iOS 11 from October onwards
- Xiaomi and Leica partner for a flagship device, Xiaomi 12 Ultra expected to launch in July
- Zomato, HDFC, HDFC Bank, Paytm and other hot stocks to watch out for on May 23